MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
← catalyst calendarNCT06097728 · readout in 820 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
863actual
Sites
151
Countries
Australia, Belgium, Brazil +18
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-09 | actual | When the study began enrolling |
| Primary completion | 2028-11-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-16 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Unresectable Pleural Mesothelioma
Interventions
- Drug: Volrustomig — also filed as MEDI5752
- Drug: Pemetrexed — also filed as Alimta
- Drug: Carboplatin — also filed as Paraplatin
- Drug: Cisplatin — also filed as Platinol
- Drug: Nivolumab — also filed as Opdivo
- Drug: Ipilimumab — also filed as Yervoy
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS) in experimental arm relative to comparator arm
measured up to approximately 61 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed